{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:22:01Z","timestamp":1793726521526,"version":"4.6.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To date, no disease modifying therapies are available for Parkinson\u2019s disease (PD). Since PD is the second most prevalent neurodegenerative disorder, there is a high demand for such therapies. Both environmental and genetic risk factors play an important role in the etiology and progression of PD. The most common genetic risk factor for PD is a mutation in the <jats:italic>GBA1<\/jats:italic>(GBA)-gene, encoding the lysosomal enzyme glucocerebrosidase (GCase). The mucolytic ambroxol is a repurposed drug, which has shown the property to upregulate GCase activity in-vitro and in-vivo. Ambroxol therefore has the potency to become a disease modifying therapy in PD, which was the reason to design this randomized controlled trial with ambroxol in PD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This trial is a single-center, double-blind, randomized, placebo-controlled study, including 80 PD patients with a GBA mutation, receiving either ambroxol 1800\u2009mg\/day or placebo for 48\u2009weeks. The primary outcome measure is the Unified Parkinson\u2019s Disease Rating Scale motor subscore (part III) of the Movement Disorder Society (MDS-UPDRSIII) in the practically defined off-state at 60\u2009weeks (after a 12-week washout period). Secondary outcomes include a 3,4-dihydroxy-6-18F-fluoro-I-phenylalanine ([<jats:sup>18<\/jats:sup>F]FDOPA) PET-scan of the brain, Magnetic Resonance Imaging (with resting state f-MRI and Diffusion Tensor Imaging), GCase activity, both intra- and extracellularly, sphingolipid profiles in plasma, Montreal Cognitive Assessment (MoCA), quality of life (QoL) measured by the Parkinson\u2019s Disease Questionnaire (PDQ-39) and the Non-Motor Symptom Scale (NMSS) questionnaire.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Ambroxol up to 1200\u2009mg\/day has shown effects on human cerebrospinal fluid endpoints, which supports at least passage of the blood-brain-barrier. The dose titration in this trial up to 1800\u2009mg\/day will reveal if this dose level is safe and also effective in modifying the course of the disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT05830396. Registration date: March 20, 2023.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-024-03629-9","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T14:41:33Z","timestamp":1714574493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation"],"prefix":"10.1186","volume":"24","author":[{"given":"O.","family":"Siemeling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Slingerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"issue":"10","key":"3629_CR1","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3109\/02699052.2011.597046","volume":"25","author":"LA Barker","year":"2011","unstructured":"Barker LA, Morton N, Morrison TG, Mcguire BE. Inter-rater reliability of the Dysexecutive questionnaire (DEX): comparative data from non-clinician respondents - all raters are not equal. Brain Inj. 2011;25(10):997\u20131004.","journal-title":"Brain Inj"},{"issue":"6","key":"3629_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA - J Am Med Assoc. 2020;323(6):548\u201360.","journal-title":"JAMA - J Am Med Assoc"},{"key":"3629_CR3","first-page":"1","volume":"1659","author":"VL Dawson","year":"2019","unstructured":"Dawson VL, Dawson TM. Promising disease-modifying therapies for Parkinson \u2019 s disease. Sci Transl Med. 2019;1659:1\u20134.","journal-title":"Sci Transl Med"},{"issue":"9996","key":"3629_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet."},{"issue":"17","key":"3629_CR5","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of Glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"issue":"9645","key":"3629_CR6","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet. 2008;372(9645):1263\u201371.","journal-title":"Lancet."},{"issue":"1","key":"3629_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/mdc3.13098","volume":"8","author":"JM den Heijer","year":"2021","unstructured":"den Heijer JM, van Hilten JJ, Kievit AJA, Bonifati V, Groeneveld GJ. Experience in genetic counseling for GBA1 variants in Parkinson\u2019s disease. Mov Disord Clin Pract. 2021;8(1):33\u20136.","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"3629_CR8","first-page":"232","volume":"28","author":"R Duran","year":"2014","unstructured":"Duran R, Mencacci NE, Angeli AV, Deas E, Houlden H, Mehta A, et al. Europe PMC funders group the Glucocerobrosidase E326K variant predisposes to Parkinson \u2019 s disease. But Does Not Cause Gaucher \u2019 s Disease. 2014;28(2):232\u20136.","journal-title":"But Does Not Cause Gaucher \u2019 s Disease"},{"issue":"3","key":"3629_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ymgme.2011.12.002","volume":"105","author":"B Liou","year":"2012","unstructured":"Liou B, Grabowski GA. Is E326K glucocerebrosidase a polymorphic or pathological variant? Mol Genet Metab [Internet]. 2012;105(3):528\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2011.12.002.","journal-title":"Mol Genet Metab [Internet]"},{"issue":"9","key":"3629_CR10","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/mds.28112","volume":"35","author":"JM den Heijer","year":"2020","unstructured":"den Heijer JM, Cullen VC, Quadri M, Schmitz A, Hilt DC, Lansbury P, et al. A large-scale full GBA1 gene screening in Parkinson\u2019s disease in the Netherlands. Mov Disord. 2020;35(9):1667\u201374.","journal-title":"Mov Disord"},{"issue":"1","key":"3629_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s13760-022-02165-y","volume":"123","author":"G De Michele","year":"2023","unstructured":"De Michele G, Palmieri GR, Pane C, Valente EM, Palmieri I, Dello Iacovo CDP, et al. Motor and non-motor features in Parkinson\u2019s disease patients carrying GBA gene mutations. Acta Neurol Belg [Internet]. 2023;123(1):221\u20136. https:\/\/doi.org\/10.1007\/s13760-022-02165-y.","journal-title":"Acta Neurol Belg [Internet]"},{"issue":"10","key":"3629_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","volume":"73","author":"MY Davis","year":"2016","unstructured":"Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, et al. Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in parkinson disease. JAMA Neurol. 2016;73(10):1217\u201324.","journal-title":"JAMA Neurol"},{"key":"3629_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/jnnp-2020-322857","volume":"91","author":"TB Stoker","year":"2020","unstructured":"Stoker TB, Camacho M, Rhodes SW, Liu G, Scherzer CR, Foltynie T, et al. Impact of GBA1 variants on long- \u00ad term clinical progression and mortality in incident Parkinson \u2019 s disease. J Neurol Neurosurg Psychiatry. 2020;91:695\u2013702.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3629_CR14","doi-asserted-by":"crossref","unstructured":"Gegg ME, Burke D, Heales SJR, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains. Ann Neurol. 2012 Sep;72(3):455\u201363.","DOI":"10.1002\/ana.23614"},{"key":"3629_CR15","doi-asserted-by":"crossref","unstructured":"Huebecker M, Moloney EB, Spoel AC Van Der, Priestman DA, Isacson O, Hallett PJ, et al. Reduced sphingolipid hydrolase activities , substrate accumulation and ganglioside decline in Parkinson \u2019 s disease. Mol Neurodegener. 2019;14(1):40.","DOI":"10.1186\/s13024-019-0339-z"},{"issue":"May","key":"3629_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.freeradbiomed.2021.08.230","volume":"175","author":"SRL Vieira","year":"2021","unstructured":"Vieira SRL, Schapira AHV. Glucocerebrosidase mutations: a paradigm for neurodegeneration pathways \u2606. Free Radic Biol Med [Internet]. 2021;175(May):42\u201355. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.08.230.","journal-title":"Free Radic Biol Med [Internet]"},{"issue":"2018","key":"3629_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2018.09.015","volume":"121","author":"AL G\u00fcndner","year":"2019","unstructured":"G\u00fcndner AL, Duran-Pacheco G, Zimmermann S, Ruf I, Moors T, Baumann K, et al. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing \u03b1-synuclein levels. Neurobiol Dis [Internet]. 2019;121(2018):205\u201313. https:\/\/doi.org\/10.1016\/j.nbd.2018.09.015.","journal-title":"Neurobiol Dis [Internet]"},{"issue":"3","key":"3629_CR18","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"KE Murphy","year":"2014","unstructured":"Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, et al. Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease. Brain. 2014;137(3):834\u201348.","journal-title":"Brain."},{"key":"3629_CR19","doi-asserted-by":"crossref","unstructured":"Labrador-garrido A, Zhong S, Hughes L, Keshiya S, Kim WS, Halliday GM, et al. Live cell in situ lysosomal GCase activity correlates to alpha-synuclein levels in human di erentiated neurons with LRRK and GBA mutations. Front Cell Neurosci. 2023;17:1229213.","DOI":"10.3389\/fncel.2023.1229213"},{"issue":"6","key":"3629_CR20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.22400","volume":"69","author":"V Cullen","year":"2011","unstructured":"Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, et al. Acid \u03b2-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter \u03b1-synuclein processing. Ann Neurol. 2011;69(6):940\u201353.","journal-title":"Ann Neurol"},{"key":"3629_CR21","doi-asserted-by":"crossref","unstructured":"Dermentzaki G, Dimitriou E, Xilouri M, Michelakakis H, Stefanis L. Loss of \u03b2-Glucocerebrosidase activity does not affect alpha-Synuclein levels or lysosomal function in neuronal cells. PLoS One. 2013;8(4).","DOI":"10.1371\/journal.pone.0060674"},{"issue":"3","key":"3629_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","volume":"6","author":"HJR Fernandes","year":"2016","unstructured":"Fernandes HJR, Hartfield EM, Christian HC, Emmanoulidou E, Zheng Y, Booth H, et al. ER stress and Autophagic perturbations Lead to elevated extracellular \u03b1-Synuclein in GBA-N370S Parkinson\u2019s iPSC-derived dopamine neurons. Stem Cell Reports [Internet]. 2016;6(3):342\u201356. https:\/\/doi.org\/10.1016\/j.stemcr.2016.01.013.","journal-title":"Stem Cell Reports [Internet]"},{"issue":"3","key":"3629_CR23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.neuron.2021.10.032","volume":"110","author":"I Stojkovska","year":"2022","unstructured":"Stojkovska I, Wani WY, Zunke F, Belur NR, Pavlenko EA, Mwenda N, et al. Rescue of \u03b1-synuclein aggregation in Parkinson\u2019s patient neurons by synergistic enhancement of ER proteostasis and protein trafficking. Neuron [Internet]. 2022;110(3):436-451.e11. https:\/\/doi.org\/10.1016\/j.neuron.2021.10.032.","journal-title":"Neuron [Internet]"},{"key":"3629_CR24","doi-asserted-by":"crossref","unstructured":"Kuo SH, Tasset I, Cheng MM, Diaz A, Pan MK, Lieberman OJ, et al. Mutant glucocerebrosidase impairs \u03b1-synuclein degradation by blockade of chaperone-mediated autophagy. Sci Adv. 2022;8(6).","DOI":"10.1126\/sciadv.abm6393"},{"issue":"8","key":"3629_CR25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/mds.25772","volume":"29","author":"L Parnetti","year":"2014","unstructured":"Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson\u2019s disease. Mov Disord. 2014;29(8):1019\u201327.","journal-title":"Mov Disord"},{"issue":"1","key":"3629_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0336-2","volume":"14","author":"J Do","year":"2019","unstructured":"Do J, McKinney C, Sharma P, Sidransky E. Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 2019;14(1):1\u201316.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"3629_CR27","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.29163","volume":"37","author":"D te Vruchte","year":"2022","unstructured":"te Vruchte D, Sturchio A, Priestman DA, Tsitsi P, Hertz E, Andr\u00e9asson M, et al. Glycosphingolipid changes in plasma in Parkinson\u2019s disease independent of glucosylceramide levels. Mov Disord. 2022;37(10):2129\u201334.","journal-title":"Mov Disord"},{"issue":"1","key":"3629_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3233\/JPD-202310","volume":"11","author":"Y Niimi","year":"2021","unstructured":"Niimi Y, Mizutani Y, Akiyama H, Watanabe H, Shiroki R, Hirabayashi Y, et al. Cerebrospinal fluid profiles in Parkinson\u2019s disease: no accumulation of glucosylceramide, but significant downregulation of active complement C5 fragment. J Parkinsons Dis. 2021;11(1):221\u201332.","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"3629_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/mds.28846","volume":"37","author":"M Surface","year":"2022","unstructured":"Surface M, Balwani M, Waters C, Haimovich A, Gan-Or Z, Marder KS, et al. Plasma Glucosylsphingosine in GBA1 mutation carriers with and without Parkinson\u2019s disease. Mov Disord. 2022;37(2):416\u201321.","journal-title":"Mov Disord"},{"key":"3629_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.conb.2021.11.004","volume":"72","author":"I Milenkovic","year":"2022","unstructured":"Milenkovic I, Blumenreich S, Futerman AH. GBA mutations, glucosylceramide and Parkinson\u2019s disease. Curr Opin Neurobiol [Internet]. 2022;72:148\u201354. https:\/\/doi.org\/10.1016\/j.conb.2021.11.004.","journal-title":"Curr Opin Neurobiol [Internet]"},{"issue":"8","key":"3629_CR31","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/mds.26278","volume":"30","author":"ME Gegg","year":"2015","unstructured":"Gegg ME, Sweet L, Wang BH, Shihabuddin LS, Sardi SP, Schapira AHV. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov Disord. 2015;30(8):1085\u20139.","journal-title":"Mov Disord"},{"key":"3629_CR32","doi-asserted-by":"crossref","unstructured":"Blumenreich S, Nehushtan T, Barav OB, Saville JT, Dingjan T, Hardy J, et al. Elevation of gangliosides in four brain regions from Parkinson\u2019s disease patients with a GBA mutation. npj Park Dis. 2022;8(1).","DOI":"10.1038\/s41531-022-00363-2"},{"issue":"10","key":"3629_CR33","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/mds.29204","volume":"37","author":"P Lansbury","year":"2022","unstructured":"Lansbury P. The sphingolipids clearly play a role in Parkinson\u2019s disease, but nature has made it complicated. Mov Disord. 2022;37(10):1985\u20139.","journal-title":"Mov Disord"},{"issue":"2","key":"3629_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.molcel.2010.10.005","volume":"40","author":"DK Breslow","year":"2010","unstructured":"Breslow DK, Weissman JS. Membranes in balance: mechanisms of sphingolipid homeostasis. Mol Cell. 2010;40(2):267\u201379.","journal-title":"Mol Cell"},{"issue":"8","key":"3629_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1517\/17425255.4.8.1119","volume":"4","author":"M Malerba","year":"2008","unstructured":"Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008;4(8):1119\u201329.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"3629_CR36","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014;137(5):1481\u201395.","journal-title":"Brain."},{"issue":"5","key":"3629_CR37","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/1073858417748875","volume":"24","author":"R Balestrino","year":"2018","unstructured":"Balestrino R, Schapira AHV. Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications. Neuroscientist. 2018;24(5):540\u201359.","journal-title":"Neuroscientist."},{"issue":"7","key":"3629_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/syn.21967","volume":"71","author":"A Migdalska-Richards","year":"2017","unstructured":"Migdalska-Richards A, Ko WKD, Li Q, Bezard E, Schapira AHV. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse. 2017;71(7):17\u20139.","journal-title":"Synapse."},{"issue":"4","key":"3629_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K, D\u2019Souza G, Woodgate P, Elflein J, et al. Ambroxol for the treatment of patients with Parkinson disease with and without Glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020;77(4):427\u201334.","journal-title":"JAMA Neurol"},{"issue":"5","key":"3629_CR40","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/ana.24790","volume":"80","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards A, Daly L, Bezard E, Schapira AHV. Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice. Ann Neurol. 2016;80(5):766\u201375.","journal-title":"Ann Neurol"},{"issue":"2","key":"3629_CR41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/jmedgenet-2019-106132","volume":"57","author":"YM Kim","year":"2020","unstructured":"Kim YM, Yum MS, Heo SH, Kim T, Jin HK, Bae JS, et al. Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. J Med Genet. 2020;57(2):124\u201331.","journal-title":"J Med Genet"},{"key":"3629_CR42","doi-asserted-by":"crossref","unstructured":"Istaiti M, Revel-Vilk S, Becker-Cohen M, Dinur T, Ramaswami U, Castillo-Garcia D, Ceron-Rodriguez M, Chan A, Rodic P, Tincheva RS, Al-Hertani W, Lee BH, Yang CF, Kiec-Wilk B, Fiumara A, Rubio B, Zimran A. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: investigator initiated registry based on real life data. Am J Hematol. 2021;96(5):545\u201351.","DOI":"10.1002\/ajh.26131"},{"issue":"4","key":"3629_CR43","first-page":"E28535","volume":"101","author":"H Tang","year":"2022","unstructured":"Tang H, Yuan Z, Li J, Wang Q, Fan W. The application of ambroxol hydrochloride combined with fiberoptic bronchoscopy in elderly patients with severe pneumonia: a meta-analysis and systematic review. Med (United States). 2022;101(4):E28535.","journal-title":"Med (United States)"},{"key":"3629_CR44","doi-asserted-by":"crossref","unstructured":"Su W, Dong Q, Jiao F. Study on the efficacy and safety of Ambroxol combined with methylprednisolone in patients with acute lung injury. Biomed Res Int. 2021;2021.","DOI":"10.1155\/2021\/5771101"},{"issue":"23","key":"3629_CR45","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/jama.2022.21243","volume":"328","author":"NJ Butcher","year":"2022","unstructured":"Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et al. Guidelines for Reporting Outcomes in Trial Protocols The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345\u201356.","journal-title":"JAMA"},{"key":"3629_CR46","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601.","journal-title":"Mov Disord"},{"issue":"1","key":"3629_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-020-01811-3","volume":"20","author":"JM Boertien","year":"2020","unstructured":"Boertien JM, Van Der Zee S, Chrysou A, Gerritsen MJJ, Jansonius NM, Spikman JM, et al. Study protocol of the DUtch PARkinson cohort (DUPARC): a prospective, observational study of de novo Parkinson\u2019s disease patients for the identification and validation of biomarkers for Parkinson\u2019s disease subtypes, progression and pathophysiology. BMC Neurol. 2020;20(1):1\u201311.","journal-title":"BMC Neurol"},{"key":"3629_CR48","doi-asserted-by":"crossref","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129\u201370.","DOI":"10.1002\/mds.22340"},{"key":"3629_CR49","doi-asserted-by":"crossref","unstructured":"Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in parkinson\u2019s disease. Ann Neurol. 2000;47(4):493\u2013503.","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.3.CO;2-W"},{"issue":"9","key":"3629_CR50","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/mds.26251","volume":"30","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Wu IW, Buckley S, Coffey CS, Foster E, Mendick S, et al. Diffusion tensor imaging of the nigrostriatal fibers in Parkinson\u2019s disease. Mov Disord. 2015;30(9):1229\u201336.","journal-title":"Mov Disord"},{"key":"3629_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/jnc.13385","volume":"139","author":"A Migdalska-Richards","year":"2016","unstructured":"Migdalska-Richards A, Schapira AHV. The relationship between glucocerebrosidase mutations an Parkinson disease. J Neurochem. 2016;139:77\u201390.","journal-title":"J Neurochem"},{"issue":"1","key":"3629_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-33921-x","volume":"8","author":"F Atashrazm","year":"2018","unstructured":"Atashrazm F, Hammond D, Perera G, Dobson-Stone C, Mueller N, Pickford R, et al. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson\u2019s disease. Sci Rep. 2018;8(1):1\u201312.","journal-title":"Sci Rep"},{"key":"3629_CR53","doi-asserted-by":"crossref","unstructured":"Alonso A, Go M. The physical properties of ceramides in membranes. Annu Rev Biophys. 2018;47:633\u201354.","DOI":"10.1146\/annurev-biophys-070317-033309"},{"key":"3629_CR54","doi-asserted-by":"crossref","unstructured":"den Heijer JM, Cullen VC, Pereira DR, Yavuz Y, de Kam ML, Grievink HW, et al. A biomarker study in patients with GBA1 -Parkinson\u2019s disease and healthy controls. Mov Disord. 2023;1\u201314.","DOI":"10.1002\/mds.29360"},{"issue":"07","key":"3629_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21769\/BioProtoc.3572","volume":"10","author":"LP Hughes","year":"2020","unstructured":"Hughes LP, Halliday GM, Dzamko N. Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes. Bio-Protocol. 2020;10(07):1\u201311.","journal-title":"Bio-Protocol"},{"issue":"10","key":"3629_CR56","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/mds.23823","volume":"26","author":"I Litvan","year":"2011","unstructured":"Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS task force on mild cognitive impairment in Parkinson\u2019s disease: critical review of PD-MCI. Mov Disord. 2011;26(10):1814\u201324.","journal-title":"Mov Disord"},{"key":"3629_CR57","doi-asserted-by":"crossref","unstructured":"Aarsland D. Mild cognitive impairment in Parkinson disease a multicenter pooled analysis. Neurology. 2010;75(12):1062\u20139.","DOI":"10.1212\/WNL.0b013e3181f39d0e"},{"issue":"1\u20132","key":"3629_CR58","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","volume":"289","author":"D Aarsland","year":"2010","unstructured":"Aarsland D, Wilhelm M. Journal of the neurological sciences the epidemiology of dementia associated with Parkinson disease. J Neurol Sci [Internet]. 2010;289(1\u20132):18\u201322. https:\/\/doi.org\/10.1016\/j.jns.2009.08.034.","journal-title":"J Neurol Sci [Internet]"},{"issue":"8","key":"3629_CR59","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1212\/01.wnl.0000180516.69442.95","volume":"65","author":"D Muslimovi\u0107","year":"2005","unstructured":"Muslimovi\u0107 D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239\u201345.","journal-title":"Neurology."},{"key":"3629_CR60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1468-1331.2008.02212.x","volume":"15","author":"KR Chaudhuri","year":"2008","unstructured":"Chaudhuri KR, Martinez-martin P. Quantitation of non-motor symptoms in Parkinson \u00d5 s disease. Eur J Neurol. 2008;15:2\u20138.","journal-title":"Eur J Neurol"},{"issue":"6","key":"3629_CR61","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A","volume":"15","author":"A Schrag","year":"2000","unstructured":"Schrag A, Jahanshahi M, Quinn N. How does Parkinson\u2019s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord. 2000;15(6):1112\u20138.","journal-title":"Mov Disord"},{"key":"3629_CR62","doi-asserted-by":"publisher","unstructured":"Maple-Gr\u00f8dem J, Dalen I, Tysnes O-B, Macleod AD, Forsgren L, Counsell CE, et al. Association of GBA Genotype with Motor and Functional Decline in Newly Diagnosed Patients with Parkinsons Disease. Neurology. 2020; https:\/\/doi.org\/10.1212\/WNL.0000000000011411.","DOI":"10.1212\/WNL.0000000000011411"},{"key":"3629_CR63","unstructured":"ALEA | Tools for Clinical Trials [Internet]. Available from: https:\/\/www.aleaclinical.eu\/. Accessed 5 Apr 2023."},{"issue":"8","key":"3629_CR64","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/mds.20914","volume":"21","author":"A Schrag","year":"2006","unstructured":"Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson\u2019s disease rating scale. Mov Disord. 2006;21(8):1200\u20137.","journal-title":"Mov Disord"},{"issue":"9","key":"3629_CR65","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1111\/bcp.14777","volume":"87","author":"Y Sheng","year":"2021","unstructured":"Sheng Y, Zhou X, Yang S, Ma P, Chen C. Modelling item scores of unified Parkinson\u2019s disease rating scale part III for greater trial efficiency. Br J Clin Pharmacol. 2021;87(9):3608\u201318.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03629-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03629-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03629-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T15:11:44Z","timestamp":1714576304000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03629-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3629"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03629-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The GRoningen Early-PD Ambroxol Treatment trial is performed in accordance with the Declaration of Helsinki. The study has been approved by the Medical Research Ethics Committee of the University Medical Center Groningen (METc UMCG) and is registered under METc 2022\/179. The study has been reviewed and approved by the Dutch Central Committee on Research involving Human Subjects (CCMO) as competent authority (BI) and is registered under NL77347.042.22.For all subjects, consent to participate was obtained through a written informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TvL has received grant support from the MJFF, the UMCG, Menzis, Weston Brain Institute and the Dutch Brain Foundation. Consultancy fees were received from AbbVie, Britannia Pharm., Centrapharm and Neuroderm. Speaker fees were received from AbbVie, Britannia Pharm. and Eurocept.The remaining authors declare that they have no known competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}